Immune-mediated diseases (IMIDs) are a growing global health problem affecting millions of people every year. Over $330B is spent annually in the United States on care of patients suffering from IMIDs such as Inflammatory Bowel Diseases (IBD) or Rheumatoid Arthritis (RA) alone. The Holy Grail of IMIDs is to avoid flares by early detection and optimised treatment.
NimBio is developing an AI-based disease management platform that aims to prevent flare ups and reduce patient readmissions. NimBio’s solution provides patients with a non-invasive wearable device that provides continuous measurements of inflammatory biomarkers, and accordingly improves IMIDs care.
Using non-invasive predictive tools via wearable technology, NimBio will provide an early alert for inflammatory episodes, and allow timely personalized treatments for a market of 200M patients world-wide with immune-mediated diseases, saving an estimated 15% of economic burden (~$60B). With a proven track record in the Inflammatory Bowel Diseases (IBD) field, NimBio commenced its development with IBD, a disease with one of the highest economic burden per patient.